A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
The main purpose of this study is to evaluate the safety and efficacy of abemaciclib in combination with pembrolizumab in participants with advanced non-small cell lung cancer (NSCLC) or hormone receptor positive (HR+), human epidermal growth factor receptor negative (HER2-) breast cancer.
Non Small Cell Lung Cancer|Breast Cancer
DRUG: Abemaciclib|DRUG: Pembrolizumab|DRUG: Anastrozole
Number of Participants with One or More Serious Adverse Event(s) (SAEs), Baseline through Study Treatment Completion (Approximately 6 Months)|Number of Participants with Non-Serious Adverse Event(s), Baseline through Study Treatment Completion (Approximately 6 Months)
Objective Response Rate (ORR) per RECIST v1.1: Percentage of Participants With a Complete or Partial Response, Baseline to Measured Progressive Disease or Start of New Anti-Cancer Therapy (Approximately 6 Months)|Disease Control Rate (DCR) per RECIST v1.1: Percentage of Participants With a Best Overall Response of Complete Response, Partial Response, and Stable Disease, Baseline to Measured Progressive Disease or Start of New Anti-Cancer Therapy (Approximately 6 Months)|Duration of Response (DoR) per RECIST v1.1, Date of Complete Response or Partial Response to Date of Objective Disease Progression or Death Due to Any Cause (Approximately 12 Months)|Progression Free Survival (PFS) per RECIST v1.1, Baseline to Measured Progressive Disease or Death (Approximately 10 Months)|Overall Survival (OS), Baseline to Date of Death Due to Any Cause (Approximately 18 Months)|Pharmacokinetics (PK): Mean Steady State Exposure of Abemaciclib in Combination with Pembrolizumab with or without Anastrozole, Predose Cycle One Day One through Predose Cycle Eight Day One (21 Day Cycles)
The main purpose of this study is to evaluate the safety and efficacy of abemaciclib in combination with pembrolizumab in participants with advanced non-small cell lung cancer (NSCLC) or hormone receptor positive (HR+), human epidermal growth factor receptor negative (HER2-) breast cancer.